secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202601
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio receives $50M termination fee after Candid merger terminates for UCB deal
--------------------------------------------------------------------------------

- Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.
- Rallybio entitled to $50,000,000 Parent Termination Fee plus $375,000 expense reimbursement, payable by May 4, 2026.
- Rallybio, Candid and UCB entered a waiver releasing claims and waiving certain merger rights.
- Rallybio intends to withdraw its Form S-4 registration statement filed for the merger.
- The termination fee provides immediate cash, but the merger failure is a setback for Rallybio's strategic plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/0001193125-26-202601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer